In cell and gene therapy manufacturing, the difference between a life-saving treatment reaching a patient on time and a critical delay often comes down to one factor: supply chain integration. The complexity is staggering. A single CAR-T therapy journey involves coordinating patient enrollment, apheresis scheduling, cryopreservation, transportation across multiple time zones, GMP manufacturing, quality control, final product delivery, and patient infusion, all while maintaining perfect Chain of Identity (COI) and Chain of Custody (COC) at every touchpoint. Manual coordination across these stakeholders is not just inefficient. It’s a patient safety risk. The Integration Imperative in Personalized Therapies Cell and gene …